Government-Owned Inventions; Availability for Licensing, 55906-55907 [2018-24469]

Download as PDF 55906 Federal Register / Vol. 83, No. 217 / Thursday, November 8, 2018 / Notices Dated: November 1, 2018. Jennifer M. Guimond, Project Clearance Liaison, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. [FR Doc. 2018–24465 Filed 11–7–18; 8:45 am] BILLING CODE 4140–01–P (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: November 5, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health [FR Doc. 2018–24471 Filed 11–7–18; 8:45 am] BILLING CODE 4140–01–P daltland on DSKBBV9HB2PROD with NOTICES National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Mental Health; Notice of Closed Meetings National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Eye Institute; Notice of Closed Meeting VerDate Sep<11>2014 16:51 Nov 07, 2018 Jkt 247001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel; NEI Institutional Training Grant Applications (T32 and T35). Date: November 27–28, 2018. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6700B Rockledge Drive, Ste. 3400, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Anne E. Schaffner, Ph.D., Chief, Scientific Review Branch, Division of Extramural Research, National Eye Institute, 5635 Fishers Lane, Suite 1300, Msc 9300, Bethesda, MD 20892–9300, (301) 451–2020, aes@nei.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS) Dated: November 2, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–24467 Filed 11–7–18; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00056 Fmt 4703 AGENCY: Sfmt 4703 National Institutes of Health, HHS. ACTION: DEPARTMENT OF HEALTH AND HUMAN SERVICES Name of Committee: National Institute of Mental Health Special Emphasis Panel Member Conflicts: Mental Health Services Research. Date: November 26, 2018. Time: 4:00 p.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Karen Gavin-Evans, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Boulevard, Room 6153, MSC 9606, Bethesda, MD 20892, 301–451–2356, gavinevanskm@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Rare Genetic Disorders as a Window into the Genetic Architecture of Mental Disorders. Date: November 27, 2018. Time: 10:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Vinod Charles, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606, Bethesda, MD 20892–9606, 301–443–1606, charlesvi@mail.nih.gov. Government-Owned Inventions; Availability for Licensing Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: James M. Robinson, 301–761–7542; James.Robinson4@nih.gov. Licensing information and copies of the patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Methods for diagnosing and treating Mycobacterium tuberculosis (Mtb) infection through detection of CD153 expression level. Description of Technology: Mycobacterium tuberculosis (Mtb) infection continues to be the leading cause of death due to a single infectious agent and poses significant global health challenges. Past research has shown that CD4 T cells are essential for resistance to Mtb infection, and for decades it has been thought that IFN(g) production is the primary mechanism of CD4 T cellmediated protection. NIAID researchers have discovered that the expression of TNF superfamily molecule CD153 (TNSF8) is required for control of the pulmonary Mtb infection by CD4 T cells. The results have shown that, in Mtb infected mice, CD153 expression is highest on Ag-specific Th1 cells in the lung tissue parenchyma. On the contrary, CD153 deficient mice have developed high pulmonary bacterial loads and succumb early to Mtb infection. In Mtb infected non-human primates, CD153 expression is much higher on Ag-specific CD4 T cells in the SUMMARY: E:\FR\FM\08NON1.SGM 08NON1 daltland on DSKBBV9HB2PROD with NOTICES Federal Register / Vol. 83, No. 217 / Thursday, November 8, 2018 / Notices airways compared to the blood, and the frequency of Mtb-specific CD153expressing CD4 T cells inversely correlates with bacterial loads in granulomas. Further, in Mtb infected humans, CD153 defines a subset of highly polyfunctional Mtb-specific CD4 T cells that are much more abundant in individuals with controlled latent Mtb infection compared to those with active TB. Since the expression of CD153 by CD4 T cells is a major immune mechanism of host protection against Mtb infection, the discovery can be used to effectively diagnose and treat Mtb infections in the future. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: • Mycobacterium tuberculosis diagnostic that measures the production of CD153 as an indicator of the disease and its severity • A companion diagnostic can be used to determine the effectiveness of a vaccine against a Mycobacterium tuberculosis infection in a subject • Therapeutic use to treat Mycobacterium tuberculosis in a subject Competitive Advantages: • Ability to be used as a target for Mtb diagnostics and therapeutics Development Stage: • Proof of concept in animal models and human subject. Inventors: Daniel L. Barber (NIAID), Michelle A. Sallin (NIAID), Keith D. Kauffman (NIAID) Publications: Sallin, Michelle A., et al. ‘‘Host resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 expression.’’ Nature microbiology (2018): 1. Intellectual Property: HHS Reference No. E–085–2018 US Patent Application No. 62/633,816 filed February 2, 2018 Licensing Contact: James M. Robinson, 301–761–7542; James.Robinson4@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact James M. Robison at 301–761–7542 or James.Robinson4@nih.gov. VerDate Sep<11>2014 16:51 Nov 07, 2018 Jkt 247001 Dated: October 31, 2018. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2018–24469 Filed 11–7–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Neurodevelopmental Disorders. Date: November 20, 2018. Time: 12:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Pat Manos, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5200, MSC 7846, Bethesda, MD 20892, 301–408– 9866, manospa@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Review: Cancer Behavioral Research Communication in the New Media Environment. Date: November 30, 2018. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Weijia Ni, Ph.D., Chief/ Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3100, MSC 7808, Bethesda, MD 20892, 301–594– 3292, niw@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Virology. Date: December 4–5, 2018. Time: 8:30 a.m. to 2:00 p.m. PO 00000 Frm 00057 Fmt 4703 Sfmt 9990 55907 Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Susan Daum, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, Bethesda, MD 20892, 301–827–7233, susan.boyle-vavra@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: AIDS and AIDS Related Research. Date: December 4, 2018. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Jingsheng Tuo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5207, Bethesda, MD 20892, 301–451–8754, tuoj@ nei.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Neurodegeneration. Date: December 4, 2018. Time: 10:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Afia Sultana, Ph.D., Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Room 4189, Bethesda, MD 20892, (301) 827–7083, sultanaa@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Toxicology and Pharmacology. Date: December 4, 2018. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place:National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Terez Shea-Donohue, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2180, MSC 7818, Bethesda, MD 20892, sheadonohuept@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: November 2, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–24466 Filed 11–7–18; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\08NON1.SGM 08NON1

Agencies

[Federal Register Volume 83, Number 217 (Thursday, November 8, 2018)]
[Notices]
[Pages 55906-55907]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24469]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: James M. Robinson, 301-761-7542; 
[email protected]. Licensing information and copies of the patent 
application listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Methods for diagnosing and treating Mycobacterium tuberculosis 
(Mtb) infection through detection of CD153 expression level.
    Description of Technology:
    Mycobacterium tuberculosis (Mtb) infection continues to be the 
leading cause of death due to a single infectious agent and poses 
significant global health challenges. Past research has shown that CD4 
T cells are essential for resistance to Mtb infection, and for decades 
it has been thought that IFN([gamma]) production is the primary 
mechanism of CD4 T cell-mediated protection.
    NIAID researchers have discovered that the expression of TNF 
superfamily molecule CD153 (TNSF8) is required for control of the 
pulmonary Mtb infection by CD4 T cells. The results have shown that, in 
Mtb infected mice, CD153 expression is highest on Ag-specific Th1 cells 
in the lung tissue parenchyma. On the contrary, CD153 deficient mice 
have developed high pulmonary bacterial loads and succumb early to Mtb 
infection. In Mtb infected non-human primates, CD153 expression is much 
higher on Ag-specific CD4 T cells in the

[[Page 55907]]

airways compared to the blood, and the frequency of Mtb-specific CD153-
expressing CD4 T cells inversely correlates with bacterial loads in 
granulomas. Further, in Mtb infected humans, CD153 defines a subset of 
highly polyfunctional Mtb-specific CD4 T cells that are much more 
abundant in individuals with controlled latent Mtb infection compared 
to those with active TB. Since the expression of CD153 by CD4 T cells 
is a major immune mechanism of host protection against Mtb infection, 
the discovery can be used to effectively diagnose and treat Mtb 
infections in the future.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Mycobacterium tuberculosis diagnostic that measures the 
production of CD153 as an indicator of the disease and its severity
     A companion diagnostic can be used to determine the 
effectiveness of a vaccine against a Mycobacterium tuberculosis 
infection in a subject
     Therapeutic use to treat Mycobacterium tuberculosis in a 
subject
    Competitive Advantages:
     Ability to be used as a target for Mtb diagnostics and 
therapeutics
    Development Stage:
     Proof of concept in animal models and human subject.
    Inventors: Daniel L. Barber (NIAID), Michelle A. Sallin (NIAID), 
Keith D. Kauffman (NIAID)
    Publications: Sallin, Michelle A., et al. ``Host resistance to 
pulmonary Mycobacterium tuberculosis infection requires CD153 
expression.'' Nature microbiology (2018): 1.
    Intellectual Property: HHS Reference No. E-085-2018 US Patent 
Application No. 62/633,816 filed February 2, 2018
    Licensing Contact: James M. Robinson, 301-761-7542; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize the methods of treating human 
tuberculosis. For collaboration opportunities, please contact James M. 
Robison at 301-761-7542 or [email protected].

    Dated: October 31, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-24469 Filed 11-7-18; 8:45 am]
 BILLING CODE 4140-01-P